iBio, Inc. (IBIO)
| Market Cap | 50.78M +94.6% |
| Revenue (ttm) | 1.08M +115.0% |
| Net Income | -34.88M |
| EPS | -0.27 |
| Shares Out | 64.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 262,690 |
| Open | 0.7500 |
| Previous Close | 0.7481 |
| Day's Range | 0.7483 - 0.8071 |
| 52-Week Range | 0.6751 - 3.8200 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 5.69 (+620.4%) |
| Earnings Date | Nov 10, 2026 |
About IBIO
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area... [Read more]
Financial Performance
In fiscal year 2026, iBio, Inc.'s revenue was $100,000, a decrease of -75.00% compared to the previous year's $400,000. Losses were -$33.04 million, 79.8% more than in 2025.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for IBIO stock is "Strong Buy." The 12-month stock price target is $5.69, which is an increase of 620.40% from the latest price.
News
iBio reports extended preclinical data from NHP study of IBIO-610
iBio (IBIO) announced extended preclinical data from a non-human primate, or NHP, study of IBIO-610, potentially a first-in-class Activin E antibody candidate, presented at ObesityWeek 2026, as well a...
iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences
ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.
iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
Presented additional preclinical data supporting IBIO-610's potential to drive fat selective weight loss in combination with GLP-1 therapy
iBio, Inc. Earnings release: Q1 2027
iBio, Inc. released its Q1 2027 earnings on November 10, 2026, summarizing the period's financial results.
iBio, Inc. Quarterly report: Q1 2027
iBio, Inc. has published its Q1 2027 quarterly earnings report on November 10, 2026.
iBio, Inc. Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Milestones include Q1 next-year readouts for myostatin and planned Activin E dosing, plus IBIO-800 HFpEF data and an Australian Phase I filing targeted near end-Q2. Cash runway extends into Q2 2028, with a raise anticipated next year.
iBio, Inc. Slides: Corporate presentation
iBio, Inc. has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
iBio to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmo...
iBio presents IBIO-610 data from obese non-human primate study
iBio (IBIO) highlighted preclinical body-composition data from its obese non-human primate, or NHP, study evaluating IBIO-610, alone and in combination with semaglutide, a GLP-1 receptor agonist used ...
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human tri...
iBio initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of iBio (IBIO) with a Buy rating and $7 price target The firm believes IBIO-610’s activin E antibody “looks promising.” The drug addressesa next-generation obesity, ...
iBio, Inc. Slides: Corporate presentation
iBio, Inc. has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
iBio, Inc. Transcript: Wells Fargo 21st Annual Healthcare Conference
The discussion highlighted a robust pipeline of long-acting antibodies for obesity and related diseases, with a focus on quality weight loss and muscle preservation. Key assets include a unique Activin E antibody and a myostatin-targeting molecule, both leveraging advanced discovery technologies. Major clinical milestones are expected in the next 12 months.
iBio, Inc. Proxy statement: Proxy filing
iBio, Inc. filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulm...
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmo...
iBio, Inc. Annual report: Q4 2026
iBio, Inc. has published its Q4 2026 annual report on August 28, 2026.
iBio, Inc. Earnings release: Q4 2026
iBio, Inc. released its Q4 2026 earnings on August 28, 2026, summarizing the period's financial results.
iBio, Inc. Annual report: Q4 2026
iBio, Inc. has published its Q4 2026 annual report on August 28, 2026.
iBio, Inc. Proxy statement: Proxy filing
iBio, Inc. filed a proxy statement on August 20, 2026, providing details for shareholder voting and corporate governance matters.
iBio appoints Molly Carr as chief medical officer
iBio (IBIO) announced the appointment of Molly Carr as chief medical officer as the company advances its clinical-stage cardiometabolic pipeline. Most recently, she served as clinical head and associa...
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary dis...
iBio announces new preclinical data from IBIO-610 study
iBio (IBIO) announced new preclinical data from its obese non-human primate, or NHP, study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Following a single dose of IB...
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
iBio initiated with an Outperform at Raymond James
Raymond James initiated coverage of iBio (IBIO) with an Outperform rating and $5 price target iBio’s first antibody, IBIO-600, recently entered the clinic for obesity and the firm sees IBIO-610…